In Q1 21, Faes witnessed a material sales decline in its Bilastine franchise – impacted by Q1 20 ‘forward stocking’ and decline in the anti-histamine market – which overshadowed the decent showing in other franchises and robust profitability growth. However, these trends are expected to normalise, with recovery expected from H2 21 onwards, as COVID-19 vaccination programmes gather pace. Potential upside from the success in late-stage trials of Calcifediol as a COVID-19 treatment could prove to b ....
04 May 2021
Q1 21 – a mixed bag
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q1 21 – a mixed bag
- Published:
04 May 2021 -
Author:
Amandeep Goyal -
Pages:
3
In Q1 21, Faes witnessed a material sales decline in its Bilastine franchise – impacted by Q1 20 ‘forward stocking’ and decline in the anti-histamine market – which overshadowed the decent showing in other franchises and robust profitability growth. However, these trends are expected to normalise, with recovery expected from H2 21 onwards, as COVID-19 vaccination programmes gather pace. Potential upside from the success in late-stage trials of Calcifediol as a COVID-19 treatment could prove to b ....